JPMorgan Chase & Co. Forecasts Strong Price Appreciation for BioNTech (NASDAQ:BNTX) Stock

BioNTech (NASDAQ:BNTX – Get Free Report) had its price target hoisted by analysts at JPMorgan Chase & Co. from $92.00 to $93.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 15.14% from the stock’s current price.

BNTX has been the subject of a number of other reports. Wall Street Zen upgraded shares of BioNTech from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. HC Wainwright reduced their price target on BioNTech from $130.00 to $110.00 and set a “buy” rating on the stock in a report on Monday, November 9th. Wells Fargo & Company reduced their price target on BioNTech from $140.00 to $125.00 and set an “overweight” rating on the stock in a report on Wednesday, November 4th. Berenberg Bank set a $140.00 price target on BioNTech in a research report on Wednesday, September 16th. Finally, Citigroup dropped their price objective on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and a consensus target price of $120.44.

Get Our Latest Stock Analysis on BioNTech

BioNTech Price Performance

BNTX stock opened at $80.77 on Thursday. The firm’s 50-day moving average price is $91.52 and its two-hundred day moving average price is $95.18. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The stock has a market capitalization of $20.43 billion, a price-to-earnings ratio of -11.79 and a beta of 1.28. The company has a current ratio of 8.55, a quick ratio of 8.52 and a debt-to-equity ratio of 0.01.

Insider Buying and Selling

In other news, CEO Ugur Sahin sold 72,000 shares of the firm’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $97.23, for a total value of $7,000,560.00. Following the completion of the sale, the chief executive officer directly owned 108,209 shares of the company’s stock, valued at approximately $10,521,161.07. This trade represents a 39.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 807,209 shares of company stock valued at $79,246,837. 19.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BioNTech

Hedge funds and other institutional investors have recently modified their holdings of the stock. Farther Finance Advisors LLC grew its stake in BioNTech by 31.5% in the third quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock worth $48,000 after purchasing an additional 118 shares during the period. ProShare Advisors LLC raised its holdings in BioNTech by 5.3% in the third quarter. ProShare Advisors LLC now owns 4,014 shares of the company’s stock worth $395,000 after purchasing an additional 202 shares in the last quarter. AlphaCentric Advisors LLC raised its holdings in BioNTech by 4.5% in the third quarter. AlphaCentric Advisors LLC now owns 6,547 shares of the company’s stock worth $644,000 after purchasing an additional 281 shares in the last quarter. Parallel Advisors LLC lifted its position in BioNTech by 50.3% during the third quarter. Parallel Advisors LLC now owns 843 shares of the company’s stock valued at $83,000 after buying an additional 282 shares during the period. Finally, SBI Securities Co. Ltd. lifted its position in BioNTech by 5.5% during the third quarter. SBI Securities Co. Ltd. now owns 6,863 shares of the company’s stock valued at $675,000 after buying an additional 358 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

(Get Free Report)

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally.

Further Reading

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.